Xalatan

Basic Xalatan Information

• INN (International Nonproprietary Name): Latanoprost
• Brand Names Available In United Kingdom: Xalatan; Monoprost; preservative‑free variants such as Iyuzeh and Monoprost are distributed in Europe and may be seen in UK practice via suppliers and generics.
• ATC Code: S01EE01 (S01 = Ophthalmologicals; EE = Prostaglandin analogues; 01 = Latanoprost)
• Forms & Dosages: 0.005% (0.05 mg/mL) topical ophthalmic solution in multidose dropper vials (typically 2.5 mL or 5 mL) and preservative‑free single‑dose containers.
• Manufacturers In United Kingdom: Marketed and supplied in the UK by multinational manufacturers including Viatris (Xalatan), Théa (Monoprost/Iyuzeh), and various generic suppliers such as Glenmark and Sun Pharma through UK distribution channels.
• Registration Status In United Kingdom: Latanoprost products such as Xalatan and Monoprost are registered and distributed across Europe and in countries that follow EMA standards; they are routinely included in national formularies and available via prescription in the UK.
• OTC / Rx Classification: Prescription only medicine (POM) in most countries, including EU and UK practice.

Critical Warnings & Restrictions

Who Should Be Careful? Patients often ask if latanoprost is safe for them, especially if they are elderly, pregnant or have chronic disease.

Prioritise safety: latanoprost is prescription‑only and must be started and reviewed by an ophthalmologist or GP with shared‑care arrangements on the NHS.

• Absolute Contraindications: Known hypersensitivity to latanoprost or any excipient.
• Absolute Contraindications: History of herpetic keratitis — specialist review required.

Relative risks require clinical judgement and monitoring.

• Relative Contraindications/Monitoring: Active intraocular inflammation such as uveitis.
• Relative Contraindications/Monitoring: Aphakia or pseudophakia with a torn posterior capsule (increased macular oedema risk).
• Relative Contraindications/Monitoring: Severe asthma — inform prescribers of respiratory disease as rare bronchospasm has been reported.

High-Risk Groups

• Elderly: No routine dose adjustment generally required, but monitor ocular surface changes, tolerance and adherence.
• Pregnancy and Breastfeeding: Avoid unless a specialist advises that benefit outweighs risk; prostaglandin analogues are used only when necessary.
• Chronic Illness: Patients with active ocular inflammation, recent ocular surgery or unstable systemic respiratory disease need specialist input.

Interaction With Activities

• Instillation can cause transient stinging, tearing or blurred vision and may impair driving or operation of machinery until vision clears.
• Report any ocular irritation that affects workplace precision tasks to the employer where required under UK safety rules.
• Pharmacists should counsel patients to avoid immediate driving after drops until comfortable and to report suspected adverse reactions via the Yellow Card scheme.

Q&A — Can I Drive After Taking It In The UK?

If drops cause transient blurred vision or stinging, wait until vision has cleared before driving.

Do not drive if vision is affected; inform your prescriber if problems persist.

Usage Basics

INN, Brand Names Available In The UK

INN: latanoprost is the active ingredient in Xalatan and in multiple generics distributed in the UK.

Brand examples encountered in European markets include Xalatan and Monoprost, with preservative‑free options (Iyuzeh, Monoprost single‑dose) available from certain suppliers.

Legal Classification (POM, P, GSL)

Latanoprost is classified as a Prescription Only Medicine (POM) for glaucoma and ocular hypertension in the UK.

The MHRA oversees product licensing and labelling consistent with EMA practice for long‑established products.

• INN: International Nonproprietary Name — Latanoprost.
• Brand: Trade or proprietary name — for example Xalatan, Monoprost.
• Dosage Form: Ophthalmic solution 0.005% in multidose or single‑dose containers.
• POM: Prescription Only Medicine — requires a valid prescription.

Dosing Guide

Standard Regimens (NHS Guidelines)

Typical dose is one drop of latanoprost 0.005% in the affected eye or eyes once daily, preferably in the evening.

Dosing more frequently does not improve effect and may reduce IOP‑lowering efficacy.

Therapy is chronic and continues while intraocular pressure control is required with regular IOP checks.

Adjustments For Comorbidities

• Children: limited data; consult a paediatric glaucoma specialist for off‑label use.
• Elderly: no routine dose adjustment but monitor ocular surface and adherence.
• Liver/Kidney Impairment: no formal adjustment, use with caution as systemic studies are limited.

Q&A — What If I Miss A Dose?

If you miss a dose, give it as soon as you remember on the same day.

If it is almost time for your next dose, skip the missed dose — do not double up.

• Evening Dosing Routine: Instil one drop once each evening at a consistent time to aid adherence.
• Monitoring Schedule: Baseline IOP and optic nerve assessment, early review at 4–6 weeks, then 3–12 monthly depending on stability.

Interaction Chart

Food And Drinks

Latanoprost is applied to the eye and has low systemic absorption, so no clinically significant interactions with alcohol or caffeine are documented.

Avoid using contact lenses during instillation and wait 15 minutes before reinserting lenses.

Avoid ocular cosmetics immediately around the lid margin during treatment to reduce residue trapping.

Common Drug Conflicts (MHRA Yellow Card Data)

• Immediate precautions: do not share bottles, avoid contaminating tip, and report worsening redness or respiratory symptoms.
• Report suspected adverse reactions through the MHRA Yellow Card via a pharmacist or the MHRA website.

User Reports & Trends

What Do Patients Notice? People commonly worry about cosmetic changes or how the drops feel when they first use them.

• Common patient‑reported effects include eyelash growth, darker iris or periocular pigmentation, mild redness and transient burning — findings consistent with clinical side‑effect profiles.
• Many patients appreciate once‑daily dosing and effective IOP control, while some stop therapy because of stinging, irritation or cosmetic changes.
• Preservative‑free single‑dose formulations are increasingly preferred by patients with dry eye or contact lens wearers for better comfort.

Online access via virtual consultations and online pharmacies has grown, but patients report variable counselling quality; pharmacist advice improves adherence and safety.

• When To Contact Your Healthcare Provider: Persistent pain, worsening vision, sudden visual changes, or signs of severe inflammation.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

NHS prescriptions are issued by GPs or ophthalmology clinics and dispensed at community pharmacy chains such as Boots, LloydsPharmacy and Superdrug, or at independent pharmacies.

Private prescriptions can be dispensed at the same outlets or via registered online pharmacies.

Online Pharmacies And NHS E‑Prescriptions

The NHS Electronic Prescription Service (EPS) allows collection or home delivery when pharmacies participate in the service.

Ensure any online supplier is GPhC‑registered and requires a valid prescription before supply.

In our online pharmacy, xalatan is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

• Checklist Before Ordering Online: confirm GPhC registration, valid prescription, delivery terms and pharmacist counselling availability.

Mechanism & Pharmacology

Simplified Explanation

Latanoprost is a prostaglandin F2α analogue that increases uveoscleral outflow of aqueous humour, lowering intraocular pressure.

Applied topically, it is absorbed into ocular tissues with minimal systemic exposure.

Clinical Terms

• Uveoscleral Outflow: Alternate pathway for aqueous humour drainage that latanoprost enhances.
• IOP: Intraocular pressure — the target for glaucoma treatment.
• Prostaglandin Analogue: Drug class to which latanoprost belongs.

• Onset: IOP reduction begins within hours to days; maximal effect often after several weeks of continuous dosing.
• Monitoring: regular IOP checks and optic nerve assessment to ensure target pressure is achieved.

Indications & Off-Label Uses

MHRA‑Approved Uses

Licensed indication is treatment of open‑angle glaucoma and ocular hypertension to lower intraocular pressure.

Off‑Label Practices In NHS And Private Care

• Paediatric glaucoma: limited, specialist‑led off‑label use under consultant care with informed consent.
• Preservative‑free use: selected for patients with ocular surface disease even when licensed formulations are tolerated poorly.
• Formulary switching: switching between branded and generic latanoprost is common; counsel patients about potential cosmetic or tolerability differences.

• Clinician Responsibilities When Prescribing Off‑Label: document rationale, obtain informed consent, arrange close monitoring.

Key Clinical Findings

Recent UK and EU research between 2022 and 2025 has reinforced latanoprost as a first‑line prostaglandin analogue for lowering IOP in open‑angle glaucoma and ocular hypertension.

Comparative studies show latanoprost produces IOP reductions comparable to travoprost and bimatoprost in many trials, with good tolerability.

Preservative‑free formulations demonstrate improved ocular surface signs in sensitive patients in real‑world studies and audits.

NICE and NHS guidance continue to recommend prostaglandin analogues as standard first‑line therapy for many patients requiring long‑term IOP control.

Alternatives Matrix

NHS Prescribing Alternatives

Pros And Cons Checklist

• Switching therapies: consider efficacy parity, side‑effect profiles, ocular surface and patient preference.
• Cost and formulary choices often determine first choice on the NHS; discuss cosmetic effects with patients before switching.
• For patients with asthma or respiratory disease, avoid topical beta‑blockers where possible and favour prostaglandin analogues.

Common Questions

• Will latanoprost change my eye colour?
• Answer: A gradual increase in iris pigmentation can occur, especially in mixed or heterochromic irides, and may be permanent in the treated eye.
• Can I wear contact lenses?
• Answer: Remove soft contact lenses before instillation and wait at least 15 minutes before reinsertion; preservative‑free single‑dose formats may be more comfortable.
• How soon will I notice benefit?
• Answer: IOP reduction begins within hours to days, with maximal effect after several weeks; regular monitoring determines treatment success.
• How do I report side effects?
• Answer: Contact your prescriber or pharmacist and consider MHRA Yellow Card reporting for suspected adverse reactions.

• Urgent Advice Checklist: seek immediate care for severe eye pain, sudden vision loss, increasing redness with discharge, or signs of macular oedema in pseudophakic/aphakic patients.

NHS Cost & Access Comparison Table

• Checklist: Verify local prescription exemption status (age, benefits, chronic disease), and confirm prescription validity before ordering.
• Advice: Check the NHS website or local pharmacy for up‑to‑date charges and dispensing notes.

Registration & Regulation

MHRA Approval Process

The MHRA oversees UK licensing and pharmacovigilance and many latanoprost products hold marketing authorisations consistent with historical EMA approvals.

Prescribers should follow licensed indications and local trust formularies when selecting branded or generic products.

NHS Prescribing Framework

Latanoprost is a POM and repeat dispensing or shared‑care agreements are common in chronic glaucoma management with scheduled ophthalmology reviews.

• Marketing Authorisation → MHRA labelling → NHS formulary inclusion → Prescribing and monitoring.
• Prescribers: confirm licence status, document counselling and schedule follow‑up IOP checks.

Storage & Handling

UK Household Storage (Cold / Damp Climate)

Store unopened bottles refrigerated at 2–8°C when the product labelling specifies refrigeration before opening.

After opening, store at room temperature below 25°C, protect from light and discard after the manufacturer‑specified period, commonly 4–6 weeks.

In UK homes prone to damp or variable temperatures, keep vials in their original box and away from radiators and sunlight.

Guidance From NHS And Pharmacists

• At‑Home Storage Checklist: refrigerate unopened stock if required; once opened keep below 25°C; discard after 4–6 weeks; store out of reach of children.
• Single‑dose vials: use immediately after opening and discard any unused single‑use containers.
• When travelling: follow cold‑chain advice for products that require refrigeration before opening; otherwise room temperature post‑opening is allowed within the product timeframe.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Patients commonly ask how to put the drop in without wasting it; demonstrating technique builds confidence and adherence.

Use patient‑centred, plain English instructions and demonstrate the instillation technique step‑by‑step.

NHS Patient Safety Advice

• Instillation Technique: Tilt head back, pull down lower lid to form a pocket, instil one drop, close the eye gently for 1–2 minutes and apply nasolacrimal occlusion to reduce systemic absorption.
• Contact Lenses: Remove before instillation and wait ≥15 minutes before reinserting lenses.
• Side Effects: Discuss cosmetic side effects such as eyelash growth and iris pigmentation and ensure patients know when to seek help.

• Monitoring Milestones: Baseline IOP and optic nerve assessment, review at 4–6 weeks after initiation, then ongoing checks every 3–12 months depending on disease stability.

Delivery Across United Kingdom